Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 205.50 GBp
Change Today -3.00 / -1.44%
Volume 97.3K
As of 12:09 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

horizon discovery group plc (HZD) Snapshot

Open
208.50 GBp
Previous Close
208.50 GBp
Day High
210.00 GBp
Day Low
205.50 GBp
52 Week High
01/19/15 - 236.00 GBp
52 Week Low
11/12/14 - 146.50 GBp
Market Cap
165.0M
Average Volume 10 Days
84.2K
EPS TTM
-0.09 GBp
Shares Outstanding
80.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HORIZON DISCOVERY GROUP PLC (HZD)

Related News

No related news articles were found.

horizon discovery group plc (HZD) Related Businessweek News

No Related Businessweek News Found

horizon discovery group plc (HZD) Details

Horizon Discovery Group plc, a life science company, supplies research tools to organizations engaged in genomics research and the development of personalized medicines in the United Kingdom and internationally. Its offering comprises custom generation of genetically defined cell lines; genetically defined cell lines and reporter gene cell-based assay kits; contract assay development and compound profiling services; target identification and validation services; drug discovery alliances; and the generation and supply of genomic reference materials. The company provides endogenous pathway tag and reporter cell lines for application in functional genomics research and drug discovery and development; in-vitro and in-vivo assay development and drug screening services in various areas, such as cell growth, signal transduction, apoptosis, angiogenesis, and metastasis; and genetically defined and human genomic reference standards, including FFPE cell line sections and purified gDNA. It also provides research organizations engaged in drug discovery and development with access to the unique cHTS platform and Chalice analytics software, which enables the screening and analysis of various complementary drug combinations with identifying personalized medicine solutions for the treatment of cancer. The company serves organizations engaged in bio-pharmaceutical process optimization, drug discovery and development, and clinical diagnostic development. Its customer base comprises organizations, including major pharmaceutical, biotech, and diagnostic companies, as well as academic research centers. The company was founded in 2005 and is based in Cambridge, United Kingdom.

183 Employees
Last Reported Date: 04/14/15
Founded in 2005

horizon discovery group plc (HZD) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: 122.4K GBP
Co-Founder and Member of Scientific Advisory ...
Total Annual Compensation: 122.7K GBP
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: 104.3K GBP
Compensation as of Fiscal Year 2013.

horizon discovery group plc (HZD) Key Developments

Horizon Discovery Group plc Reports Unaudited Consolidated Earnings Results for the Year Ended December 31, 2014

Horizon Discovery Group plc reported unaudited consolidated earnings results for the year ended December 31, 2014. For the period, the company reported revenue was £11,904,574 against £6,646,113 a year ago. Operating loss was £6,109,810 against £2,929,064 a year ago. Loss before tax was £6,072,912 against £3,042,886, a year ago. Loss for the year was £5,923,471 against £2,970,277, year ago. Basic and diluted loss per share was 9.2 pence against 7.5 pence, a year ago. Net cash outflow from operating activities was £6,472,724 against £2,222,168 a year ago. Purchases of property, plant and equipment was £1,947,711 against £897,285 a year ago. Purchase of intangible assets was £6,254,740 against £133,716 a year ago.

Horizon Discovery Group plc, 2014 Earnings Call, Apr 14, 2015

Horizon Discovery Group plc, 2014 Earnings Call, Apr 14, 2015

Horizon Discovery Group plc and Archerdx, Inc. Signs Original Equipment Manufacture (OEM) Agreement

Horizon Discovery Group plc and ArcherDX Inc. announced they have signed an Original Equipment Manufacture (OEM) agreement that will see Horizon's Reference Materials supplied as a standalone product alongside ArcherDX's Archer(TradeMark)FusionPlex (TradeMark) to aid customer validation of its ALK fusion assay kits. The agreement is a further endorsement of the demand in the translational sequencing market for accurate and reliable reference material to validate sample testing. Horizon's reference materials will be available for sale alongside Archer(TradeMark) FusionPlex(TradeMark) ALK fusion tests that can run on both Illumina(Registered) and Ion Torrent(TradeMark) next-generation sequencing platforms, a fast-growing market that represented $2.5 billion in 2014 and Horizon anticipates that the Archer assay will prove to be well received by the market. Further financial details of the deal were not disclosed. The Archer(TradeMark) FusionPlex(TradeMark) ALK, RET, ROS1 Panel simultaneously detects and identifies both known and previously unidentified fusions and mutations of human ALK, RET and ROS1 (c-ros oncogene 1) genes from tumour samples, including formalin fixed paraffin embedded (FFPE) preserved specimens. ALK fusions of genetic markers ALK, RET, ROS1, are found in approximately 3-7% of lung tumours and are an important clinical marker for non-small cell lung cancer. The anti-cancer drug Crizotinib, marketed by Pfizer, acts as an ALK and ROS1 inhibitor and is approved to treat certain late-stage non-small cell lung cancers that express the abnormal anaplastic lymphoma kinase (ALK) gene, alongside an approved companion diagnostic. It is therefore essential to have accurate and reliable molecular diagnostic testing prior to beginning therapy.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HZD:LN 205.50 GBp -3.00

HZD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HZD.
View Industry Companies
 

Industry Analysis

HZD

Industry Average

Valuation HZD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.1x
Price/Book 2.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 13.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HORIZON DISCOVERY GROUP PLC, please visit www.horizondiscovery.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.